

# Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development

Reena J. Papat,<sup>1</sup> Seran Hakki,<sup>1</sup> Alpesh Thakker,<sup>2</sup> Alice M. Coughlan,<sup>3</sup> Julie Watson,<sup>4</sup> Mark A. Little,<sup>3</sup> Corinne M. Spickett,<sup>2</sup> Paul Lavender,<sup>4</sup> Behdad Afzali,<sup>1</sup> Claudia Kemper,<sup>1</sup> and Michael G. Robson<sup>1</sup>

<sup>1</sup>Division of Transplant Immunology and Mucosal Biology, MRC Centre for Transplantation, King's College London, Guy's Hospital, Great Maze Pond, London, United Kingdom. <sup>2</sup>School of Life & Health Sciences, Aston University, Aston Triangle, Birmingham, United Kingdom. <sup>3</sup>Trinity Health Kidney Centre, Department of Clinical Medicine, Trinity College Dublin, St. James' Hospital Campus, Dublin, Ireland. <sup>4</sup>MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, Great Maze Pond, London, United Kingdom.

**Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is characterized by the presence of autoantibodies to myeloperoxidase and proteinase-3, which bind monocytes in addition to neutrophils. While a pathological effect on neutrophils is acknowledged, the impact of ANCA on monocyte function is less well understood. Using IgG from patients we investigated the effect of these autoantibodies on monocytes and found that anti-myeloperoxidase antibodies (MPO-ANCA) reduced both IL-10 and IL-6 secretion in response to LPS. This reduction in IL-10 and IL-6 depended on Fc receptors and enzymatic myeloperoxidase and was accompanied by a significant reduction in TLR-driven signaling pathways. Aligning with changes in TLR signals, oxidized phospholipids, which function as TLR4 antagonists, were increased in monocytes in the presence of MPO-ANCA. We further observed that MPO-ANCA increased monocyte survival and differentiation to macrophages by stimulating CSF-1 production. However, this was independent of myeloperoxidase enzymatic activity and TLR signaling. Macrophages differentiated in the presence of MPO-ANCA secreted more TGF- $\beta$  and further promoted the development of IL-10- and TGF- $\beta$ -secreting CD4<sup>+</sup> T cells. Thus, MPO-ANCA may promote inflammation by reducing the secretion of antiinflammatory IL-10 from monocytes, and MPO-ANCA can alter the development of macrophages and T cells to potentially promote fibrosis.**

## Introduction

Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a systemic disease with clinical manifestations that include crescentic glomerulonephritis and pulmonary hemorrhage (1). The name ANCA vasculitis reflects the fact that it is characterized by autoantibodies against neutrophils (2). However, these autoantibodies bind to the proteins myeloperoxidase (MPO) (3) or proteinase-3 (PR3) (4), which are found within granules not only in neutrophils but also in monocytes. The evidence that ANCAs are pathogenic comes from in vitro studies in which IgG from patients with anti-MPO or anti-PR3 antibodies activate neutrophils to undergo respiratory burst and degranulation, as first shown by Falk et al. (5) and confirmed by others (reviewed in ref. 6). In vivo support for the pathogenicity of ANCA is provided by studies in which injection of anti-MPO antibodies causes focal necrotizing crescentic glomerulonephritis in mice in a neutrophil-dependent manner (7, 8). However, the effects of ANCA on MPO- and PR3-expressing monocytes have received far less attention.

Monocytes and macrophages are present within early segmental lesions seen on renal biopsies from patients with ANCA vasculitis (9). Therefore, it is important to understand the effects of ANCA on monocytes, as this may contribute to both tissue inflammation and fibrosis. Fibrosis is an important clinical issue in both the lung and kidney, with glomerular sclerosis being closely linked to renal prognosis (10). There are data to suggest functional effects of ANCA on monocytes. Ralston and colleagues described the production of IL-8 in response to PR3-ANCA (11) and O'Brien et al. recently described the production of IL-1 $\beta$ , IL-6, and IL-8 by TNF- $\alpha$ -primed monocytes in response to MPO-ANCA but not to PR3-ANCA (12).

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Submitted:** March 2, 2016

**Accepted:** December 12, 2016

**Published:** January 26, 2017

**Reference information:**

*JCI Insight.* 2017;2(2):e87379.

doi:10.1172/jci.insight.87379.

Furthermore, production of oxygen radicals by TNF- $\alpha$ -primed monocytes in response to MPO or PR3-ANCA has been described (13). In addition to a pathogenic role for ANCA, cellular immunity is also considered to be important in ANCA vasculitis, with a role for effector CD4<sup>+</sup> cells demonstrated in a murine model (14). Therefore, the effect of monocytes and macrophages on CD4<sup>+</sup> T cell activation and how this may be modified by ANCA is also an important question.


Here, we investigated the effect of ANCA on human peripheral blood monocytes and found that MPO-ANCA impacted at least on 2 levels on monocyte function and that these functional deviations are likely to play a significant role in pathogenesis. MPO-ANCA reduced secretion of antiinflammatory IL-10 by monocytes (and may hence further foster local inflammation) and also induced development of macrophages that instruct CD4<sup>+</sup> T cells, which could contribute to the tissue fibrosis observed in vasculitis.

## Results

*MPO-ANCA decreases IL-10 and IL-6 production from monocytes in response to LPS.* We examined the effect of a large panel of unselected MPO-ANCA, PR3-ANCA, and control IgG (11, 9, and 10 per group, respectively) on peripheral blood monocytes isolated from 5 healthy donors (see Supplemental Table 1 for patient characteristics; supplemental material available online with this article; doi:10.1172/jci.insight.87379DS1). To mirror the situation where ANCA bind monocytes in the context of an inflammatory response, we stimulated monocytes with LPS and explored whether ANCA modulated the response to LPS. We measured a panel of cytokines in the supernatant of stimulated monocytes stimulated with or without LPS in the presence of control IgG or ANCA for 18 hours. After incubation with MPO-ANCA or control IgG but without LPS, none of the indicated cytokines were detectable (data not shown). With LPS, while we did not observe an effect of MPO-ANCA on IL-8 and MIP-1 $\alpha$  production by monocytes, and its effects on TNF- $\alpha$  and IL-1 $\beta$  production were variable among donors, both IL-6 and IL-10 were consistently and significantly decreased by MPO-ANCA across all 5 donors, with the most profound effect seen for IL-10. Addition of PR3-ANCAs only had a consistent downmodulatory effect on IL-10, which was less marked than that of MPO-ANCA (Figure 1). In summary, MPO-ANCA led to a consistent reduction in both IL-6 and IL-10 production by monocytes in response to LPS, while PR3-ANCA only reduced IL-10 but not IL-6 secretion in LPS-primed monocytes. Furthermore, we confirmed that this effect of MPO-ANCA was due to MPO binding activity using affinity-purified antibody (Supplemental Figure 1.)


*The effect of MPO-ANCA on monocytes depends on Fc receptors and enzymatic MPO.* Previously described effects of ANCA on neutrophils have been reported to require Fc receptor binding and involve interaction with the  $\beta$ 2 integrin CD18/CD11b, the complement receptor 3 (CR3) (15–17). We therefore examined if this was also the case for the observed effects of MPO-ANCA on monocytes. We generated F(ab)<sub>2</sub> fragments from 4 MPO-ANCAs and 2 control IgGs and compared responses towards these F(ab)<sub>2</sub> fragments with whole IgG (Figure 2A) using monocytes from 2 healthy donors. While the MPO-ANCA whole-IgG fraction elicited the expected reduction in IL-6 and IL-10, the addition of MPO-ANCA F(ab)<sub>2</sub> failed to have any effect on IL-6 or IL-10, strongly indicating that co-engagement of the Fc receptors on the cell surface is also needed for MPO-ANCA effects on monocytes. Interestingly, and in contrast with observations in neutrophils (17), co-engagement of CR3 is not required for MPO-ANCA-induced reduction of IL-6 and IL-10, as blockade of CD18 and/or CD11b did not impact on altered cytokine production (Figure 2B, experiments in 3 monocyte donors).

Importantly, the MPO-specific portion of MPO-ANCA is equally critical to their monocyte modulatory effects, as is the presence of enzymatically active MPO on monocytes. When we incubated monocytes ( $\pm$  LPS) with exogenously added MPO protein, MPO-ANCA, or control IgG, in the presence or absence of the specific MPO inhibitor AZD5904 (18), we found that both MPO-ANCA and exogenous MPO caused a reduction in IL-6 and IL-10 that is reversed by AZD5904 in a dose-dependent manner (Figure 3A and Supplemental Figure 2). The effects varied between the 4 monocyte donors tested. Overall, the reduction in IL-10 and IL-6 was not as marked for exogenous MPO as for MPO-ANCA, and the effect of AZD5904 was stronger for exogenous MPO. These differences could potentially reflect differing local concentrations of MPO at the monocyte cell membrane with MPO-ANCA and exogenous MPO, respectively. These data suggest that MPO-ANCA is inhibiting IL-6 and IL-10 release in response to LPS by a mechanism dependant on the increased enzymatic activity of MPO. To assess our hypothesis that MPO-ANCA may tether MPO released by activated monocytes to the cell surface, we assessed the




**Figure 1. MPO-ANCA decreases IL-10 and IL-6 production from monocytes in response to LPS.** Cytokine production from peripheral blood monocytes incubated for 18 hours with 100 ng/ml LPS and anti-myeloperoxidase antibodies (MPO-ANCA), anti-proteinase-3 antibodies (PR3-ANCA), or control IgG ( $n = 9-11$  of each type). Experiments were performed in 5 different healthy monocyte donors. Not activated (NA; no LPS) and LPS-only treated cells are shown in the same column, with the LPS-only data being the higher point in all cases. All other groups contained LPS in addition to the stated type of IgG preparation. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  by 1-way ANOVA and Dunnett's post-test with control IgG as the control group. Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.

surface expression of MPO by flow cytometry in the presence of MPO-ANCA or control IgG and also measured the concentration of MPO in the supernatant of cultured activated monocytes. Addition of MPO-ANCA indeed led to a decrease in free MPO in the supernatant (Figure 3B), with a concomitant increase in cell surface MPO expression (Figure 3C). This increase in cell surface MPO expression did not reflect increased monocyte activation as, in the same experiments, expression of CD11b and CD14 was not higher in MPO-ANCA compared with control IgG-treated samples (data not shown). We also detected immune complexes containing MPO and IgG in the supernatants of monocytes cultured with MPO-ANCA, which further supported our hypothesis (Supplemental Figure 3). In summary, these data suggest that MPO-ANCA may anchor MPO to the surface of the monocyte via Fc receptor binding and thereby facilitate or increase the action of MPO enzyme on the cell surface.




**Figure 2. The effect of MPO-ANCA on monocytes depends on Fc receptors but not CD11b or CD18.** (A) IL-10 and IL-6 production from peripheral blood monocytes incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 4$ ) or control IgG ( $n = 2$ ) compared with the effect of F(ab)<sub>2</sub> preparations of the same IgG preparations. NA, not activated (no LPS). All other groups contained LPS in addition to the stated type of IgG preparation. (B) IL-10 and IL-6 production from peripheral blood monocytes incubated for 18 hours with LPS and MPO-ANCA ( $n = 4$ ) or control IgG ( $n = 4$ ) in the presence of CD11b- or CD18-blocking antibodies. We also tested the effect of combined CD11b and CD18 blockade, with controls shown for no-antibody control and isotype-control monoclonal. ns, not significant. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  by 2-tailed Student's  $t$  test. Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.

*MPO-ANCA inhibits TLR signaling pathways.* IL-6 has been shown to promote IL-10 secretion in T cells (19, 20) and we therefore assessed whether the reduction in IL-10 production by monocytes upon ANCA-MPO addition was secondary to the reduction in IL-6. However, in monocytes IL-6 seems not to drive IL-10 production, as addition of exogenous IL-6 to cultures during activation failed to increase IL-10 production (Figure 4A).



**Figure 3. The effect of MPO-ANCA on monocytes depends on enzymatic MPO.** (A) The effect of varying doses of the myeloperoxidase (MPO) inhibitor AZD5904 on IL-6 and IL-10 production from peripheral blood monocytes incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 2$ ) or control IgG ( $n = 2$ ), with the experiment performed in 4 different monocyte donors. Exogenous MPO ( $2 \mu\text{g/ml}$ ) with and without AZD5904 ( $400 \text{ nM}$ ) was also added to monocytes incubated with LPS. Supplemental Figure 2 shows a dose-response curve for AZD5904 and exogenous MPO. (B) MPO measured by ELISA in the supernatant of peripheral blood monocytes incubated for 18 hours with LPS and MPO-ANCA ( $n = 10$ ) or control IgG ( $n = 10$ ). NA, not activated (no LPS). (C) Flow cytometry histograms of MPO on peripheral blood monocytes incubated for 2 hours with LPS and MPO-ANCA ( $n = 2$ , mean fluorescence intensities [MFIs] 160 and 206) or control IgG ( $n = 2$ , MFIs 100 and 99). MPO expression was measured in 2 additional monocyte donors under the same conditions and results were similar. Donor 2: MPO-ANCA ( $n = 2$ , MFIs 617 and 660) or control IgG ( $n = 2$ , MFIs 416 and 423). Donor 3: MPO-ANCA ( $n = 2$ , MFIs 249 and 259) or control IgG ( $n = 2$ , MFIs 219 and 192).  $***P < 0.001$  by 2-tailed Student's  $t$  test. Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.


hour, we observed only 12 genes that were differentially expressed between the groups, with a threshold of 1.75 in either direction. However, at 6 hours this rose to 566 genes (Figure 4B, with genes listed in Supplemental Table 2). Functional annotation analysis revealed that the altered gene expression profile was enriched overall for biological processes involved in immune cell activation and inflammatory responses (Figure 4C). Likewise, these analyses demonstrated that one of the most prominently affected KEGG pathways is in genes regulated by TLR signaling (Figure 4D). A gene set enrichment analysis (GSEA) was carried out (21, 22), comparing expression of all genes expressed by MPO-ANCA-treated and control IgG-treated monocytes in our arrays for enrichment of genes in the KEGG TLR signaling pathway, and we found that these genes were preferentially inhibited in the MPO-ANCA-treated cells (Figure 4E). The leading edge or core genes inhibited in this gene set are shown in Figure 4F. Specific examination of the expression of genes known to be regulated by LPS or by the Myd88 pathways using ingenuity pathway analysis (IPA) confirmed a profound inhibitory effect on these genes engendered by the presence of MPO-ANCA relative to control IgG. Z scores for LPS and Myd88 were  $-4.96$  and  $-2.22$ , respectively, and overlap  $P$  values for LPS and Myd88 were  $1.87 \times 10^{-58}$  and  $1.56 \times 10^{-9}$ , respectively (see also Supplemental Figures 4



**Figure 4. MPO-ANCA inhibits TLR signaling pathways.** (A) The effect of exogenous IL-6 on IL-10 secretion from peripheral blood monocytes incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 2$ ) or control IgG ( $n = 2$ ). NA, not activated (no LPS). All other groups contained LPS in addition to the stated type of IgG preparation. (B) Volcano plot comparing monocytes activated for 6 hours with either MPO-ANCA ( $n = 3$ ) or control IgG ( $n = 3$ ) in the presence of LPS. Threshold for significance is 1.75-fold change in either direction and  $P < 0.05$ . The 566 differentially expressed transcripts are highlighted in orange (listed in Supplemental Table 2). (C and D) Gene Ontology (C) and KEGG pathway (D) functional annotation analysis of the differentially expressed genes, showing the top 6 terms for each. (E) Gene set enrichment analysis (GSEA) for enrichment of genes in the KEGG TLR signaling pathway between MPO-ANCA-treated and control IgG-treated monocytes. (F) Heat map of the core-enriched genes from the GSEA in E. NES, normalized enrichment score; FDR, false discovery rate. In panel A,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.

and 5). Therefore, MPO-ANCA caused a general reduction in normal LPS/TLR-triggered TLR-mediated pathways regulating monocyte activation, which as a net result affected at minimum the production of IL-6 and IL-10 by these cells.

*MPO-ANCA generates oxidized phospholipids.* Since MPO is a powerful oxidant that can oxidize phospholipids to form a variety of products (23, 24), and under certain conditions oxidized phospholipids are antagonists of LPS-induced TLR4 activation (25–27), we hypothesized that MPO-ANCA might bind released MPO at the plasma membrane and lead to the generation of oxidized phospholipids. These may be responsible for blocking the effect of LPS. To support this hypothesis, we investigated whether incubation with MPO-ANCA altered the phospholipid profile of LPS-stimulated monocytes and led to increased generation of oxidized phospholipids. We incubated monocytes with LPS and MPO-ANCA ( $n = 3$ ) or control IgG ( $n = 3$ ) for 18 hours, extracted phospholipids, and assessed the phosphatidylcholine (PC) profile using liquid chromatography/mass spectrometry (LCMS). Treatment with MPO-ANCA did not affect the native phospholipid profile, and a variety of chain-shortened oxidized phospholipids were



**Figure 5. MPO-ANCA generates oxidized phospholipids.** (A) The most abundant oxidized phospholipids extracted from peripheral blood monocytes incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 3$ ) or control IgG ( $n = 3$ ). The data are presented as a percentage of the intensity of the native saturated phospholipid dipalmitoylphosphatidylcholine at  $m/z$  734 in each sample.  $*P < 0.05$  by 2-tailed Student's  $t$  test. (B) Extracted ion chromatograms (XICs) for the control IgG-treated ( $n = 3$ ) and MPO-ANCA-treated ( $n = 3$ ) samples, showing the intensity of the long-chain oxidized phospholipid species at  $m/z$  828.8 eluting at  $\sim 29.5$  minutes, ahead of nonoxidized species of the same  $m/z$  ratio. The labels above the peaks indicate their respective area as calculated by Peakview software. Based on these characteristics, the early eluting species at  $m/z$  828.8 was identified (arrow) as 1-palmitoyl-2-(epoxyisoprostane E2)-sn-glycero-3-phosphocholine (PEIPC). The XICs were prepared with a window of 0.7 Da and without smoothing. (C) Surface E06 staining on peripheral blood monocytes incubated for 18 hours with LPS and MPO-ANCA ( $n = 3$ ) or control IgG ( $n = 3$ ). (D) Mean fluorescence intensity (MFI) data from the experiment shown in C and 2 other monocyte donors to give 3 monocyte donors in total. The effect of adding the MPO inhibitor AZD5904 ( $4 \mu\text{M}$ ) to MPO-ANCA-treated monocytes is also shown. Control IgG was compared with MPO-ANCA using a 2-tailed Student's  $t$  test. MPO-ANCA was compared with MPO-ANCA + AZD5904 using a 2-tailed paired Student's  $t$  test (with lines indicating paired samples).  $*P < 0.05$ . Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.


observed in both control IgG- and MPO-ANCA-incubated monocytes (Supplemental Figure 6). Figure 5A shows the relative intensities of 8 oxidatively modified and lyso-PC species that were found to be most abundant. Supplemental Table 3 gives assignments of the PCs based on their mass-to-charge ratio ( $m/z$ ) and retention time. The data are presented as a percentage of the signal of the saturated phospholipid

dipalmitoyl PC at  $m/z$  734, as this is relatively resistant to oxidative damage. This approach allows correction for variability in the total phospholipid content of the samples and provides a better assessment of the levels of oxidized species within the total phospholipid pool. For most of the oxidatively modified and lyso-PC species, there was no significant difference in their relative abundance between control IgG-treated and MPO-ANCA-treated monocytes, and the levels of some commonly observed chain-shortened oxidized PCs such as 1-palmitoyl-2-oxovaleroyl-PC (POVPC) and 1-palmitoyl-2-glutaroyl-PC (PGPC) were on the limit of detection. However, it was found that a PC species at  $m/z$  828.8 eluting in the range of long-chain oxidized phospholipids was significantly higher in MPO-ANCA-treated monocytes (Figure 5A). Figure 5B shows extracted ion chromatograms (XICs) for  $m/z$  828.8 for each of the 6 samples. This phospholipid was tentatively identified as 1-palmitoyl-2-(5,6-epoxyisoprostane  $E_2$ )-PC (PEIPC). We next investigated the presence of oxidized phospholipids using flow cytometry. We reasoned that this technique was more accessible, allowing us to study multiple donors. Having found some oxidized phospholipids at the limit of detection with MS, it could also be more sensitive, as the oxidized phospholipid is being detected directly on the cell surface. E06 is a monoclonal antibody that binds 1-palmitoyl-2-(5'-oxo-valeroyl)-*sn*-glycero-3-phosphocholine (POVPC) (28). In experiments with 3 monocyte donors, we found that MPO-ANCA significantly increased E06 staining in LPS-primed monocytes (Figure 5, C and D). This inhibition of this effect by AZD5904 was statistically significant in 1 donor with a trend in 2 others (Figure 5D), suggesting a role for enzymatic MPO. Thus, using 2 different techniques, we have found evidence of oxidized phospholipid, which is increased in MPO-ANCA-treated monocytes and can function as a potential TLR4 antagonist, and hence explain the reduced TLR gene expression signature in the presence of MPO-ANCA (Figure 4).

*MPO-ANCA causes an increase in monocyte survival and differentiation to macrophages by increasing CSF-1 expression.* While monitoring cultures we noticed that monocytes treated with MPO-ANCA were more abundant than those treated with control IgG. Based on these observations, we next explored the effect of MPO-ANCA on monocyte survival and differentiation. To avoid the potential skewing (M1 or M2) effects of growth factor addition, we performed these experiments in the absence of LPS and in the presence of 10% human type AB serum, which has been shown to support monocyte-to-macrophage differentiation in cultures in an unbiased fashion (29). Using 10 MPO-ANCA and 10 control IgG that were also used in the previous experiments, we found that MPO-ANCA significantly increased cell survival after 6 days in culture using monocytes from 2 distinct donors (Figure 6A). Since macrophage colony stimulating factor (M-CSF; CSF-1) is a key survival and differentiation factor for monocytes and macrophages, we measured production of this factor by monocytes. We found indeed a marked increase in *CSF1* mRNA expression in the presence of MPO-ANCA compared with control IgG (Figure 6B). The importance of CSF-1 is supported by the finding that addition of the CSF-1 receptor inhibitor GW2580 caused a dose-dependent reversal of the increase in cell numbers at day 6 (Figure 6C). We next assessed whether the MPO-ANCA/CSF-1-driven effects on monocyte proliferation depended on enzymatic MPO, as we had found this to be the case for the reduction in IL-6 and IL-10. The MPO inhibitor AZD5904 did not prevent the increase in *CSF1* mRNA expression due to MPO-ANCA, which in fact was greater (Figure 6B). Despite the increase in *CSF1* expression, AZD5904 caused a decrease in macrophages at day 6 in the presence of MPO-ANCA (Figure 6D). This suggests that AZD5904 has inhibitory effects on monocyte/macrophage differentiation, unrelated to *CSF1*. Since MPO-ANCA had been shown to interfere with TLR signaling pathways (Figure 4), and human serum contains endogenous ligands for TLR2 and TLR4, we assessed if the observed effect on differentiation and survival was the result of TLR4 antagonism. However, combined blockade of TLR2 and TLR4 with neutralizing Abs had no effect on cell survival (Figure 6E). Overall, these data show a marked increase in cell proliferation after peripheral blood monocytes are incubated for 6 days with MPO-ANCA compared with control IgG. The effect is largely due to an MPO-ANCA-mediated increase in CSF-1 secretion, which itself seems independent of MPO enzymatic activity.

*Macrophages differentiated in the presence of MPO-ANCA express increased CD206, secrete TGF- $\beta$ , and promote CD4<sup>+</sup> T cell production of IL-10 and TGF- $\beta$ .* To explore the functional consequences of the effect on MPO-ANCA during macrophage maturation in human serum, we measured cytokines in the supernatant at day 6 in culture. IL-10, IFN- $\gamma$ , IL-17A, IL-2, IL-4, IL-6, and TNF- $\alpha$  were undetectable (data not shown). However, TGF- $\beta$  was detected at levels above that found in the culture medium, and was specifically increased in the presence of MPO-ANCA (Figure 7A). Furthermore, expression of the macrophage marker CD206 was induced in both MPO-ANCA- and control IgG-treated cultures but was higher with MPO-ANCA






**Figure 6. MPO-ANCA causes an increase in monocyte survival and differentiation to macrophages by increasing CSF-1 expression.** (A) Number of cells remaining after culturing peripheral blood monocytes with 10% human type AB serum and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 10$ ) or control IgG for 6 days ( $n = 10$ ) without LPS. Results are shown for 2 healthy monocyte donors. (B) CSF-1 gene expression in peripheral blood monocytes after 18 hours in culture MPO-ANCA or control IgG, with and without the MPO inhibitor AZD5904 (400 nM). (C) The effect of varying concentrations of the CSF-1 receptor inhibitor GW280 on cell number in the presence of MPO-ANCA ( $n = 2$ ) or control IgG ( $n = 2$ ). (D) The effect of the MPO inhibitor AZD5904 (400 nM) on cell number after peripheral blood monocytes were cultured for 6 days in 10% AB serum in the presence of MPO-ANCA ( $n = 3$ ) or control IgG ( $n = 3$ ). (E) The effect of TLR2/4 blockade on cell number after 6 days in 10% AB serum in the presence of MPO-ANCA ( $n = 3$ ) or control IgG ( $n = 3$ ). \* $P < 0.05$ , \*\*\* $P < 0.001$  by 2-tailed Student's  $t$  test. Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples.

(Figure 7B). This difference in CD206 expression was apparent after only 3 days in culture (Supplemental Figure 7). This observation, together with the lower CD80 expression induction we observed in MPO-ANCA-treated monocytes (Figure 7B), suggests that macrophages maturing in the presence of MPO-ANCA have an M2 phenotype in keeping with the role that we have shown for CSF-1 (Figure 6), which is known to favor M2 macrophage skewing (30).

Patients with vasculitis have T cells within affected glomeruli (31) and also changes in and/or persistence of local Th1 and Th2 responses (32). Therefore, to investigate potential effects of MPO-ANCA-exposed macrophages on CD4<sup>+</sup> T cells, we transferred supernatants from antibody-treated macrophages to CD4<sup>+</sup> T cells during anti-CD3 and anti-CD28 stimulation and measured cytokine production by stimulated CD4<sup>+</sup> T cells. While IL-17A was not consistently affected by macrophage-derived factors (Supplemental Figure 8) and IL-4 was not detected (not shown), we observed a consistent decrease in IFN- $\gamma$  production accompanied with an increase in IL-10 specifically in T cells activated in the presence of supernatants from MPO-ANCA-treated macrophages, with a statistically significant and persistent increase in the IL-10 to IFN- $\gamma$  ratio (Figure 7C). In addition, TGF- $\beta$  levels in the T cell supernatants were increased when the T cells were stimulated in the presence of supernatants from MPO-ANCA-treated macrophages (Figure 7C). The TGF- $\beta$  levels were higher than those found in the macrophage supernatants or the basal T cell medium and so they reflected production from T cells. Overall these data show that in the presence of MPO-ANCA and AB serum, peripheral blood monocytes differentiate into macrophages with an M2-like phenotype that express high levels of CD206, reduced CD80, and secrete increased TGF- $\beta$ . Furthermore, such MPO-ANCA-conditioned macrophages induce IL-10 and TGF- $\beta$  production in activated CD4<sup>+</sup> T cells, which could potentially increase fibrosis.



**Figure 7. Macrophages differentiated in the presence of MPO-ANCA express increased CD206, secrete TGF- $\beta$ , and promote CD4<sup>+</sup> T cell production of IL-10 and TGF- $\beta$ .** (A) TGF- $\beta$  in the supernatants of macrophages that developed from monocytes after 6 days in culture with 10% human type AB serum and anti-myeloperoxidase antibodies (MPO-ANCA) ( $n = 3$ ) or control IgG ( $n = 3$ ). Experiments were performed with monocytes from 2 donors. (B) Expression of CD206 and CD80 on macrophages that developed after 6 days in culture with 10% AB serum with control IgG ( $n = 2$ ) or MPO-ANCA ( $n = 2$ ). Experiments were performed with monocytes from 2 healthy donors with histograms shown for 1 donor. CD206 mean fluorescence intensities (MFIs) for donor 1 were 3,182 and 3,227 (MPO-ANCA) and 2,202 and 2,624 (Control IgG). CD206 MFIs for donor 2 were 33,466 and 33,287 (MPO-ANCA) and 20,565 and 8,357 (Control IgG). CD80 MFIs for donor 1 were 222 and 228 (MPO-ANCA) and 419 and 465 (Control IgG). CD80 MFIs for donor 2 were 1,113 and 1,213 (MPO-ANCA) and 2,413 and 3,806 (Control IgG). (C) Peripheral blood CD4<sup>+</sup> T cells were stimulated for 3 and 5 days with anti-CD3 and anti-CD28 in the presence or absence of added supernatant from monocyte/macrophages cultured with no added IgG ( $n = 1$ ), control IgG ( $n = 3$ ), or MPO-ANCA ( $n = 3$ ). The ratio of IL-10 to IFN- $\gamma$  is indicated, with TGF- $\beta$  concentrations. Concentrations of IL-10, IFN- $\gamma$ , and IL-17A are shown in Supplemental Figure 8. Experiments were performed with CD4<sup>+</sup> T cells from 2 donors, each using macrophage supernatants from different experiments. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  by 2-tailed Student's  $t$  test. Error bars represent mean  $\pm$  SEM. For a given monocyte donor,  $n$  is the number of IgG preparations from different individuals. They are not technical replicates or repeated measures of the same IgG samples. SN, supernatant.

## Discussion

We have discovered some effects of MPO-ANCA on human monocytes with potential implications for pathogenesis in ANCA vasculitis. These include a marked reduction in both IL-6 and IL-10 in response to TLR4 stimulation in monocytes, which depends on MPO enzymatic activity and is possibly mediated by an MPO-driven increase in oxidized phospholipids. MPO catalyzes oxidation reactions and can produce a variety of oxidized lipids with bioactive effects (33). The PC species at  $m/z$  828.8 that was increased in MPO-ANCA-treated monocytes was tentatively identified as PEIPC, which

has been reported previously to be generated in LPS-stimulated monocytes and neutrophils (34). We also demonstrated an increase in POVPC using the monoclonal antibody E06. Oxidized phospholipids have been shown to have a wide variety of bioactivities, including effects on leukocytes. It is now well established that these effects can be both pro- and antiinflammatory, and depend both on the specific oxidized phospholipid and the cell type (23). One important antiinflammatory mechanism of oxidized PAPC products is through inhibition of TLR2 and TLR4 signaling, as they interfere with LPS and lipopeptide signaling via LBP, sCD14, mCD14, and MD2 (25–27, 35). It has been reported previously that both PEIPC and POVPC, similarly to other oxidized phospholipids, can inhibit LPS-induced E-selectin expression in endothelial cells, at concentrations approximately 10-fold lower than those that induce IL-8 production (27, 36). Interestingly, studies on the role of oxidized phospholipids in immune responses to leprosy have found that PEIPC was able to inhibit human monocyte function in a TLR2-dependent manner (37). PEIPC is indeed one of the most abundant esterified products produced during oxidation of PAPC *in vitro*, and has also been detected as a major product in inflammatory lesions, as would be found in ANCA vasculitis (24).

Evidence was found for the presence of POVPC on the cell surface by flow cytometry and for free PEIPC in whole-cell extracts, but this does not preclude the occurrence or importance of other oxidized phospholipids or oxidized phospholipid adducts. Currently, it is not clear why a significant increase was only observed for a single oxidized species using MS. If MPO-ANCA tethers MPO to the cell surface, this would cause localized oxidation that might not be readily apparent in extracts of total cellular phospholipids. In addition, some oxidized phospholipids can be interconverted and further metabolized, which may also have contributed to variability in the analysis and limited the number of statistically significant findings. We would also stress that we are not excluding that MPO-ANCA also affects additional pathways that contribute to the observed phenotype.

The effects of IL-6 are difficult to predict. The biology of IL-6 is complex and this cytokine has both proinflammatory and antiinflammatory effects mediated by classical and by *trans*-signaling via a soluble receptor (38). For example IL-6 regulates neutrophil recruitment to inflammatory sites by promoting granulopoiesis (39), but following neutrophil recruitment and soluble IL-6 receptor shedding, IL-6 signaling on stromal cells will limit neutrophil influx (40). In contrast, IL-10 is undeniably an antiinflammatory cytokine and moreover the reduction in its level was more pronounced than that seen for IL-6. Many mechanisms are in place to prevent exaggerated inflammatory responses and IL-10 has proved to be an essential factor in this protection (41). For example, animals that are genetically deficient in IL-10 or are treated with antibodies that neutralize IL-10 die rapidly when infected with pathogens due to the overproduction of proinflammatory cytokines rather than a lack of control of infection (42, 43). In the context of tissue inflammation in ANCA vasculitis, cells such as tissue macrophages, dendritic cells, epithelial cells, and renal mesangial cells do not contain MPO and will not be affected by MPO-ANCA. However, they will be influenced by cytokines released locally by monocytes. A reduction in monocyte IL-10 would therefore be expected to increase the responsiveness of these cells to stimulation by TLRs and other inflammatory stimuli and to lead to an exaggerated inflammatory response. This protective effect of IL-10 is demonstrated in the context of renal inflammation in the unilateral ureteral obstruction model. More severe inflammation develops in the kidney of mice lacking IL-10 compared with wild-type controls (44). Overall, the dominant effect of MPO-ANCA on monocytes is a reduction in IL-10 secretion, which would be expected to promote inflammation and disease in patients.

The TLR4 inhibition observed is specific, as demonstrated by the lack of effect on cytokines other than IL-6 and IL-10. Interesting parallels exist between our work and recent data on monocytes in patients with chronic recurring multifocal osteomyelitis (CRMO) (45, 46). CRMO is an autoinflammatory condition characterized by sterile inflammation in bone with systemic symptoms. In these patients, monocytes fail to produce IL-10 in response to stimulation with LPS (45), whereas production of proinflammatory cytokines including TNF- $\alpha$  and IL-6 are unaffected. Monocytes from CRMO patients had impaired ERK1/2 activation and sp-1 recruitment to the *IL-10* gene promoter (46). The phenotype of CRMO monocytes was reproduced by treatment with an ERK1/2 inhibitor at a concentration having a submaximal effect. At this concentration, IL-10 was reduced with no effect on TNF- $\alpha$ . The molecular mechanism leading to reduced ERK1/2 activation and sp-1 expression was not established in this study. However, this previous work does demonstrate that attenuated TLR4 signaling can lead to a reduction in IL-10, with no effect seen on proinflammatory cytokines.

We also showed that MPO-ANCA causes an increase in survival and differentiation of monocytes to M2-like macrophages in culture primarily through an increase in CSF-1 production. Macrophages play an important role in wound healing as well as fibrosis. They stimulate and activate fibroblasts to produce extracellular matrix proteins (reviewed in ref. 47). It is increasingly recognized that the phenotype of macrophages does not fall into a simple M1 or M2 category (48). However, the increased expression of CD206 and reduced CD80, with TGF- $\beta$  secretion, suggests that the macrophages fit most closely with an M2-like phenotype, consistent with their induction by an increased concentration of CSF-1 (49). TGF- $\beta$  has been established for over a decade as a key cytokine that promotes the induction of regulatory T cells (50), and this has been confirmed by subsequent reports. There has been relatively little work on the induction of regulatory T cells by macrophages. In mice, macrophages polarized to secrete TGF- $\beta$  have been shown to inhibit adriamycin-induced nephrosis by a mechanism that includes the induction of regulatory T cells (51). A further report has also shown that human M2 macrophages can induce CD4<sup>+</sup> T cells with a regulatory phenotype (52). In both of these examples, the mechanism of suppression was thought to require cell contact, whereas we have shown the effect of a soluble factor in the supernatant. Nonetheless, there are parallels with our data suggesting that M2 macrophages, generated from monocytes incubated with MPO-ANCA, limit T cell activation via TGF- $\beta$ .

Our current data suggest that macrophages generated from MPO-ANCA-stimulated monocytes act to limit the activation of IFN- $\gamma$ -producing CD4<sup>+</sup> T cells and promote the switch to an IL-10-producing phenotype. Over the past few years we have described the life cycle of a Th1 CD4<sup>+</sup> cell as it changes from producing predominantly IFN- $\gamma$  to producing both IFN- $\gamma$  and IL-10 and then to producing predominantly IL-10 and acquiring suppressive capacity, with switching enhanced by ligation of CD46 (53). This represents a key pathway in the life cycle of Th1 cells as they switch from an inflammatory to a regulatory phenotype. These IL-10-secreting CD4<sup>+</sup> T cells may be similar to, if not the same as, those that have been called induced regulatory T cells (54). We have found that CD46-activated CD4<sup>+</sup> T cells indeed express increased TGF- $\beta$  (C Kemper, unpublished data). We now show that CD4<sup>+</sup> T cells activated in the presence of supernatants from MPO-ANCA-stimulated monocytes/macrophages also produce TGF- $\beta$ . T cells have been shown to be important in both pulmonary (55) and renal fibrosis (56), with several potential mechanisms that have not been fully defined. A direct effect of TGF- $\beta$  produced by T cells is one possibility and we have shown how this may be promoted by MPO-ANCA via its actions on monocytes. Effects of TGF- $\beta$  include a direct stimulation of fibroblasts to cause differentiation into myofibroblasts with concomitant collagen secretion (57). The amount of fibrosis remaining in vital end organs such as the lung and kidney is a major prognostic factor for patients with ANCA vasculitis (10).

Throughout the experiments presented in this paper, we have used IgG from healthy donors as a control. We found that F(ab)<sub>2</sub> MPO-ANCA failed to have any effect on IL-6 and IL-10 secretion (Figure 2A) and that immune complexes were formed by MPO-ANCA (Supplemental Figure 3). Therefore, an additional informative control would have been to use similarly sized immune complexes with an irrelevant antigen. Further work will be required to assess if at least some of the effects we have described are reproduced by immune complexes containing other antigens.

In summary, we have shown 2 effects of MPO-ANCA on monocytes with implications for disease in patients. These are firstly, a reduction in IL-10 in response to LPS stimulation, potentially due to inhibition of TLR signaling by oxidized phospholipids, which are known to be TLR4 antagonists. We acknowledge that, although our data are consistent with this model, we have not proved that oxidized phospholipids are acting as TLR4 antagonists in this context. Secondly, MPO-ANCA, by stimulating CSF-1 production, promotes monocyte survival and differentiation to macrophages, which instruct the generation of regulatory T cells that produce IL-10 and TGF- $\beta$  and may promote fibrosis. Further characterization of the phenotype of the human macrophages induced by MPO-ANCA, and in vivo work in murine models, will clarify the potential clinical importance of both of these effects.

## Methods

*Purification of IgG from patients and controls and generation of F(ab)<sub>2</sub> fragments.* Blood or plasma exchange fluid was obtained from patients with ANCA vasculitis or healthy controls and plasma stored at -80°C. Fibrinogen was precipitated by adding 18 g/100 ml of sodium chloride and IgG was purified with protein G chromatography (GE Healthcare). The endotoxin concentration in the final IgG preparations was measured

by Lonza using a LAL kinetic chromogenic assay. For all 30 polyclonal IgGs used, the endotoxin was less than 0.25 eU/250 µg IgG. The concentration of IgG used for all neutrophil and monocyte assays was 250 µg/ml. To generate F(ab)<sub>2</sub> fragments, whole IgG was buffer exchanged using PD10 columns into 20 mM sodium acetate and digested using immobilized pepsin (Thermo Fisher Scientific). The F(ab)<sub>2</sub> fragments were separated from undigested IgG using protein A affinity columns (GE Healthcare). SDS-PAGE demonstrated the purity of whole IgG and the F(ab)<sub>2</sub> fragments. Before all assays, IgG preparations were centrifuged at 16,000 *g* for 30 minutes at 4°C to remove aggregates. In mechanistic experiments where smaller numbers of IgG samples were used, these were taken from this full set of 30 samples.

*Monocyte and CD4<sup>+</sup> T cell isolation.* Peripheral blood mononuclear cells of healthy human controls were isolated from heparinized whole blood by Ficoll-Paque (GE Healthcare) density gradient centrifugation. Peripheral blood mononuclear cells were aspirated. Monocytes and CD4<sup>+</sup> T cells were isolated using magnetic CD14 and CD4 microbeads, respectively (Miltenyi Biotec), according to the manufacturer's instructions.

*Monocyte culture.* Monocytes were resuspended at  $1 \times 10^6$  cells/ml in RPMI 1640 media containing 10% FBS (Sigma-Aldrich) for 18-hour cultures, or human type AB serum (PAA Labs) for 6-day cultures, and 1% penicillin/streptomycin (Thermo Fisher Scientific). Monocytes were cultured in 48-well plates for selective time periods with or without 100 ng/ml LPS (from *Escherichia coli*, O55:B5, Sigma-Aldrich, L6529) and polyclonal ANCA or control IgG at a final concentration of 250 µg/ml. The cells were incubated at 37°C for varying time points, after which supernatants were collected and cell counts were performed. When used, inhibitors were added prior to the addition of ANCA or control IgG. MPO inhibitor AZD5904 (provided by AstraZeneca) and CSF-1 receptor inhibitor GW2580 (BioVision) were reconstituted in DMSO, with a final DMSO concentration of less than 0.1%. Blocking antibodies were anti-CD11b clone ICRF44 (10 µg/ml), anti-CD18 clone TS1/18 (10 µg/ml) (both Biolegend), and control IgG1 clone 107.3 (BD Biosciences). TLR2/4 blocking and control antibodies were from Invivogen (neutralizing TLR2 Ab clone B4H2, neutralizing TLR4 Ab clone W7C11, and isotype control clone T9C6) and BD Biosciences (isotype control clone 107.3) used at 10 µg/ml each. MPO was detected in monocyte supernatants by ELISA (R&D Systems DuoSet) according to the manufacturer's instructions. MPO added to the culture in the experiment shown in Figure 5 was from Calbiochem. Recombinant IL-6 was from Biolegend. For macrophage phenotyping, cells were detached using 5 mM EDTA in PBS.

*Flow cytometry.* Samples were analyzed using a FACSCanto flow cytometer (BD Biosciences) with FACSDiva software (BD Biosciences). At least 10,000 events were collected per sample and data were analyzed using FlowJo software (TreeStar). Antibodies used for flow cytometry were: MPO (clone 5B8, BD Biosciences), CD14 (clone M5E2, BD Biosciences), CD11b (clone D12, BD Biosciences), CD80 (clone 2D10, Biolegend), CD206 (clone 15-2, Biolegend), and TopFluor-E06 (Avanti Polar Lipids). For E06 staining, DAPI was used to exclude dead cells.

*CD4<sup>+</sup> T cell stimulation.* T cells were activated in 48-well plates coated with antibodies against CD3 (2 µg/ml, clone OKT-3, produced in house from a hybridoma line) and CD28 (2 µg/ml, clone CD28.2, BD Biosciences). The medium was the same composition as the monocyte medium. A final concentration of 10 U/ml recombinant IL-2 was added. Supernatants from the monocyte-to-macrophage differentiated cells were used at a ratio of 2:1 with the T cells. Supernatants were harvested at days 3 and 5 to assay the cytokine profile.

*Cytokine assays and ELISAs.* Th1, Th2, and Th17 cytokines were measured with a Cytokine Bead Array (BD Biosciences) using a FACScalibur (BD Biosciences) and analyzed using CellQuest Pro. IL-1β, IL-8, MIP-1α, CSF-1, and TGF-β levels were measured by ELISA (R&D Systems DuoSet) according to the manufacturer's instructions.

*Microarray experiments.* RNA was isolated from  $5 \times 10^5$  monocytes incubated with 100 ng/ml LPS (from *Escherichia coli*, O55:B5, Sigma-Aldrich, L6529) and MPO-ANCA or control IgG (250 µg/ml) for 6 hours using a Qiagen Allprep kit according to the manufacturer's instructions. Potential genomic DNA contamination was removed by Turbo DNase treatment (Ambion/Life Technologies). Total RNA (5 ng per sample) was amplified and reverse transcribed and labeled using an Ovation Pico WTA System V2 and Encore BiotinIL Kits (NuGen Inc.). The cDNA was hybridized to Illumina HT12V4 microarrays, scanned using an Illumina iScan System, and subjected to quantile normalization within the Genome Studio Suite v1.0 (Illumina). Expression data were analyzed using Genomics Suite (Partek Inc.) version 6.6, IPA (Qiagen), and GSEA (Broad Institute of MIT and Harvard). All original microarray data were deposited in the NCBI's Gene Expression Omnibus (GEO GSE89153).

**Cellular lipid extraction.** Monocytes from a healthy donor were incubated with anti-MPO or control IgG for 18 hours as described above ( $3 \times 10^6$  cells/condition). The cell pellets were washed and stored at  $-80^\circ\text{C}$ . All organic solvents used were of HPLC grade. Extraction of phospholipids was performed using a double-extraction technique by addition of 0.5 ml ice-cold methanol containing 0.005% butylated hydroxytoluene and 0.5 ml ultra-high-purity water. The sample was vortexed and 100  $\mu\text{l}$  of a 1  $\mu\text{g}/\text{ml}$  solution of 1,2-ditridecanoyl-*sn*-glycero-3-phosphocholine (13:0, 13:0 PC) in methanol containing 0.005% butylated hydroxytoluene was added to each sample. The samples were sonicated at  $4^\circ\text{C}$  for 15 minutes. Chloroform (500  $\mu\text{l}$ ) was added and the samples were sonicated further as described above. The samples were then centrifuged for 5 minutes at 14,500  $g$  and the upper aqueous phase was removed and re-extracted as above. Both organic phases (bottom layer) were combined, dried under a stream of oxygen-free nitrogen, and stored at  $-80^\circ\text{C}$ . Before analysis, the extracts were reconstituted in 0.2 ml methanol/chloroform (1:1).

**Phospholipid analysis by LCMS.** Phospholipids were separated by reverse phase chromatography on an HPLC system (Dionex Ultimate 3000) controlled by Chromleon software, using a Proswift RP-4H column (1 mm  $\times$  250 mm) at room temperature. The eluents used were (A) aqueous 0.1% formic acid containing 5 mM ammonium formate and (B) methanol containing 0.1% formic acid and 5 mM ammonium formate. The LCMS run time was 50 minutes with a chromatographic gradient of 70% B from 0 to 4 minutes, followed by a 3-step gradient increase to 80% B at 8 minutes, 90% B at 15 minutes, and 100% B at 20 minutes. The gradient was maintained at 100% B until 38 minutes and then decreased back to 70% B by 50 minutes. The flow of the mobile phase was set to 50  $\mu\text{l}/\text{minute}$ . Samples were diluted 5-fold or 10-fold in the starting solvent and 10  $\mu\text{l}$  was loaded onto the column. The phospholipids were detected using targeted and data-dependent scanning routines performed on an AB SCIEX 5500 QTrap mass spectrometer controlled by Analyst software. Precursor ion scanning (PIS) of 184 Da was carried out over the mass range 400–1,000 Da to identify PC and oxidized PC. The declustering potential was set to 50 V for all scans and collision energy for PIS was set to 45 eV. Information-dependent data acquisition (IDA) was used to collect MS/MS data based on the following criteria: the most intense ion with +1 charge and minimum intensity of 1,000 cps was chosen for analysis, using dynamic exclusion for 20 seconds after 2 occurrences and a fixed collision energy setting of 47 eV. Other source parameters were adjusted to give optimal response from the direct infusion of a dilute solution of standards.

Data analysis was performed manually using Peakview 2.0 software by generating XICs for individual  $m/z$  ratios corresponding to different modified and unmodified phospholipid species and calculating peak area. The peak area was normalized to that of the internal standard to check for extraction variability, but subsequently the signal intensities were expressed as a percentage of the intensity of the dipalmitoyl PC at  $m/z$  734 to take into account variability in the total phospholipid present in the samples.

**Reverse transcription quantitative PCR (RT-qPCR).** RNA was isolated from monocytes incubated with MPO-ANCA or control IgG  $\pm$  LPS for 18 hours using a Qiagen RNeasy mini kit according to the manufacturer's instructions. RNA (200 ng) was converted to cDNA using a RevertAid H Minus kit (Thermo Fisher Scientific) and stored at  $-80^\circ\text{C}$ . Hydrolysis probes (TaqMan) were used (Thermo Fisher Scientific). The first strand cDNA obtained was amplified using the recommended TaqMan primer/probe mastermix in 384-well plates using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems) in duplicate. The sequence detector SDS 2.4 software (Applied Biosystems) was used to export the Ct values (threshold cycle). The reference gene bGus was used as an endogenous control. The comparative Ct method was used ( $2^{-\Delta\Delta C_t}$ ) for quantification.

**Statistics.** Prism (GraphPad software) was used for statistical analysis, with statistical tests used indicated in the figure legends. Some data were logarithmically transformed before analysis if the variances of the groups were significantly different. Differences were considered significant if  $P$  was less than 0.05. Where a Student's  $t$  test was used it was 2 tailed.

**Study approval.** Blood samples from patients and healthy donors were taken following informed consent with ethical approval (NRES committee London—London Bridge 09/H084/72).

## Author contributions

RP, SH, MR, AT, and JW performed experiments. CS analyzed the mass spectrometry data. ML and AC generated and characterized the affinity-purified anti-MPO IgG. PL and BA analyzed the microarray data. MR, CK, and RP conceived the project and designed experiments. All authors analyzed data. MR wrote the manuscript. All authors edited the manuscript and approved the final version.

## Acknowledgments

This work was funded by an MRC/Kidney research clinical training fellowship to RP (MR/K000977/1). BA was supported by an Intermediate Clinical Research Fellowship from the Wellcome Trust (097261/Z/11/Z). The research was also supported by the Medical Research Council (MRC) Centre for Transplantation, King's College London, UK (MRC grant MR/J006742/1), and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. We are grateful to patients and colleagues at Kent and Canterbury, Royal Sussex County, King's College, and St. Helier and Guy's and St. Thomas' hospitals for help obtaining patient samples. AZD5904 was provided by AstraZeneca AB.

Address correspondence to: Michael G. Robson, Division of Transplant Immunology and Mucosal Biology, MRC Centre for Transplantation, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Phone: 0044.207188.6768; E-mail: Michael.robson@kcl.ac.uk.

- Booth AD, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. *Am J Kidney Dis.* 2003;41(4):776–784.
- Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? *Br Med J (Clin Res Ed).* 1982;285(6342):606.
- Falk RJ, et al. Myeloperoxidase specific anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA). *Neth J Med.* 1990;36(3–4):121–125.
- Lüdemann J, Utecht B, Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastolytic enzyme. *J Exp Med.* 1990;171(1):357–362.
- Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. *Proc Natl Acad Sci USA.* 1990;87(11):4115–4119.
- Kettritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. *Clin Exp Immunol.* 2012;169(3):220–228.
- Xiao H, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *J Clin Invest.* 2002;110(7):955–963.
- Coughlan AM, Freeley SJ, Robson MG. Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis. *Clin Exp Immunol.* 2012;169(3):229–237.
- Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. *Clin J Am Soc Nephrol.* 2015;10(1):54–62.
- Berden AE, et al. Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol.* 2010;21(10):1628–1636.
- Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fc gamma receptors. *J Clin Invest.* 1997;100(6):1416–1424.
- O'Brien EC, et al. Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1 $\beta$  secretion in response to anti-MPO antibodies. *Sci Rep.* 2015;5:11888.
- Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. *Arthritis Rheum.* 2001;44(7):1698–1706.
- Ruth AJ, et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. *J Am Soc Nephrol.* 2006;17(7):1940–1949.
- Jerke U, et al. Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation. *J Biol Chem.* 2011;286(9):7070–7081.
- Reumaux D, Vossebeld PJ, Roos D, Verhoeven AJ. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. *Blood.* 1995;86(8):3189–3195.
- Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fc gamma receptors and CD18. *J Am Soc Nephrol.* 2004;15(3):796–808.
- Tidén AK, et al. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. *J Biol Chem.* 2011;286(43):37578–37589.
- McGeachy MJ, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. *Nat Immunol.* 2007;8(12):1390–1397.
- Stumhofer JS, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol.* 2007;8(12):1363–1371.
- Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA.* 2005;102(43):15545–15550.
- Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet.* 2003;34(3):267–273.
- Greig FH, Kennedy S, Spickett CM. Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. *Free Radic Biol Med.* 2012;52(2):266–280.
- Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stöckl J. Generation and biological activities of oxidized

- phospholipids. *Antioxid Redox Signal*. 2010;12(8):1009–1059.
25. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. *Nature*. 2002;419(6902):77–81.
  26. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. *J Biol Chem*. 2008;283(36):24748–24759.
  27. von Schlieffen E, et al. Multi-hit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids. *Arterioscler Thromb Vasc Biol*. 2009;29(3):356–362.
  28. Hörkkö S, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. *J Clin Invest*. 1999;103(1):117–128.
  29. Netea MG, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. *Blood*. 2009;113(10):2324–2335.
  30. Vlassoff M. A rejoinder to S. K. Datta and J. B. Nugent. *Popul Stud (Camb)*. 1984;38(3):510–512.
  31. Cunningham MA, Huang XR, Dowling JP, Tipping PG, Holdsworth SR. Prominence of cell-mediated immunity effectors in “pauci-immune” glomerulonephritis. *J Am Soc Nephrol*. 1999;10(3):499–506.
  32. Abdulhad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. *Arthritis Res Ther*. 2011;13(4):236.
  33. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. *J Lipid Res*. 2009;50 Suppl:S346–S351.
  34. Jerlich A, Schaur RJ, Pitt AR, Spickett CM. The formation of phosphatidylcholine oxidation products by stimulated phagocytes. *Free Radic Res*. 2003;37(6):645–653.
  35. Erridge C, Webb DJ, Spickett CM. Toll-like receptor 4 signalling is neither sufficient nor required for oxidised phospholipid mediated induction of interleukin-8 expression. *Atherosclerosis*. 2007;193(1):77–85.
  36. Oskolkova OV, et al. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. *J Immunol*. 2010;185(12):7706–7712.
  37. Cruz D, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. *J Clin Invest*. 2008;118(8):2917–2928.
  38. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol*. 2015;16(5):448–457.
  39. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. *Blood*. 1997;90(7):2583–2590.
  40. Hurst SM, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity*. 2001;14(6):705–714.
  41. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol*. 2001;19:683–765.
  42. Hunter CA, et al. IL-10 is required to prevent immune hyperactivity during infection with *Trypanosoma cruzi*. *J Immunol*. 1997;158(7):3311–3316.
  43. Gazzinelli RT, et al. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4<sup>+</sup> T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. *J Immunol*. 1996;157(2):798–805.
  44. Jin Y, Liu R, Xie J, Xiong H, He JC, Chen N. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. *Lab Invest*. 2013;93(7):801–811.
  45. Hofmann SR, et al. Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. *Clin Immunol*. 2011;141(3):317–327.
  46. Hofmann SR, Morbach H, Schwarz T, Rösen-Wolff A, Girschick HJ, Hedrich CM. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. *Clin Immunol*. 2012;145(1):69–76.
  47. Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. *Clin Transl Med*. 2015;4:2.
  48. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014;6:13.
  49. Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity*. 2014;41(1):14–20.
  50. Chen W, et al. Conversion of peripheral CD4<sup>+</sup>CD25<sup>-</sup> naive T cells to CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med*. 2003;198(12):1875–1886.
  51. Cao Q, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. *J Am Soc Nephrol*. 2010;21(6):933–942.
  52. Savage ND, et al. Human anti-inflammatory macrophages induce Foxp3<sup>+</sup> GITR<sup>+</sup> CD25<sup>+</sup> regulatory T cells, which suppress via membrane-bound TGFbeta-1. *J Immunol*. 2008;181(3):2220–2226.
  53. Cardone J, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. *Nat Immunol*. 2010;11(9):862–871.
  54. Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. *Trends Immunol*. 2011;32(6):278–286.
  55. Luzina IG, Todd NW, Iacono AT, Atamas SP. Roles of T lymphocytes in pulmonary fibrosis. *J Leukoc Biol*. 2008;83(2):237–244.
  56. Tapmeier TT, et al. Pivotal role of CD4<sup>+</sup> T cells in renal fibrosis following ureteric obstruction. *Kidney Int*. 2010;78(4):351–362.
  57. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. *Semin Liver Dis*. 2010;30(3):245–257.